
Optimised active substances against RSV
OPERA research project launched to further develop antiviral active substances

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
The LISA Summer School 2026 takes place from 23 August to 11 September 2026. Registration is open until 31 March.
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Sánchez-Maldonado J, Macauda A, Cabrera-Serrano A, Thomsen H, Güler M, Horst R, van Guelpen B, Vodicka P, Landi S, Chattopadhyay S, Ünal P, Ruiz-Durán L, Casabonne D, Goldschmidt H, Serin I, Carretero-Fernández M, Cabezudo E, Reyes-Zurita F, Norman A, García-Sanz R, Capurso G, Hoffmann P, Pettersson-Kymmer U, Jiménez-Romera F, Rajkumar S, Weinhold N, Vodickova L, Langer C, Stein A, Karismaz A, Moreno V, Nöthen M, Jöckel K, Tavano F, Martínez-López J, Kumar S, Gutiérrez-Bautista J, Basso D, Späth F, Benavente Y, Hildebrandt M, Schmidt B, Sevcikova T, Reis R, Li Y, López-Nevot M, Netea M, Campa D, Clay-Gilmour A, Slager S, Hemminki K, Vachon C, Försti A, Canzian F, Sainz J
Waqas F, S da Costa L, Zapatero-Belinchón F, Carter-Timofte M, Lasswitz L, van der Horst D, Möller R, Dahlmann J, Olmer R, Geffers R, Gerold G, Olagnier D, Pessler F
Elwy A, Abdelrahman H, Specht J, Ewert G, Friebus-Kardash J, Dhiman S, Falkenstein J, Christ T, Wiebeck E, Shamoon A, Leimkühler N, Gramberg T, Russ A, Kalinke U, Kuang F, Sutter K, Kopf M, Mack M, Hansen W, Nimmerjahn F, Lang K
The project is developing methods to specifically transport antibiotics into cells such as alveolar macrophages, which are important in Mycobacterium tuberculosis infections. The aim is to overcome resistance and reduce side effects.
The project is researching how the effect of monoclonal antibodies can be improved. These antibodies are already being used successfully against viruses. The aim is to optimize the so-called Fc effector functions in order to fight infections even more effectively.
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.
We develop high-throughput screening assays to identify antiviral molecules against RSV and SARS-CoV-2. We use compound libraries, investigate new mechanisms of action and strive for innovative therapies.

